{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:13:15Z","timestamp":1783750395897,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01666-w","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:20:10Z","timestamp":1782746410000},"page":"943-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics"],"prefix":"10.1007","volume":"65","author":[{"given":"Maheshwari","family":"Periyasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1790-6103","authenticated-orcid":false,"given":"Mirunalini","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"7","key":"1666_CR1","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.3390\/pharmaceutics15071863","volume":"15","author":"V Perlik","year":"2023","unstructured":"Perlik V, Kulasekaran A, Coutinho G, Votava M, Cardot JM. Relationship between pharmacokinetic profile and clinical efficacy data of three different forms of locally applied flurbiprofen in the mouth\/throat. Pharmaceutics. 2023;15(7):1863.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1666_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/cpt.2174","volume":"110","author":"L Fang","year":"2021","unstructured":"Fang L, Uppoor R, Xu M, Sharan S, Zhu H, Tampal N, et al. Use of partial area under the curve in bioavailability or bioequivalence assessments: a regulatory perspective. Clin Pharmacol Ther. 2021;110(4):880\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1666_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1208\/s12248-012-9397-7","volume":"14","author":"EM Stier","year":"2012","unstructured":"Stier EM, Davit BM, Chandaroy P, Chen ML, Fourie-Zirkelbach J, Jackson A, et al. Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations. AAPS J. 2012;14(4):925\u20136.","journal-title":"AAPS J"},{"issue":"5","key":"1666_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/cpt.3561","volume":"117","author":"R Hopefl","year":"2025","unstructured":"Hopefl R, Gong Y, Bielski E, Pillai VC, Newman B, Qin B, et al. A 2024 update on US FDA implementation of partial area under the curve into bioavailability and bioequivalence assessments. Clin Pharmacol Ther. 2025;117(5):1185\u201393.","journal-title":"Clin Pharmacol Ther"},{"key":"1666_CR5","unstructured":"CFR. Definitions. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-314\/subpart-A\/section-314.3. Accessed on 08 May 2025."},{"issue":"11","key":"1666_CR6","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1023\/A:1015842425553","volume":"9","author":"ML Chen","year":"1992","unstructured":"Chen ML. An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm Res. 1992;9(11):1380\u20135.","journal-title":"Pharm Res"},{"issue":"4","key":"1666_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1208\/s12248-022-00726-w","volume":"24","author":"AJ Jackson","year":"2022","unstructured":"Jackson AJ, Foehl HC. A simulation study of the comparative performance of partial area under the curve (pAUC) and partial area under the effect curve (pAUEC) metrics in crossover versus replicated crossover bioequivalence studies for Concerta and Ritalin LA. AAPS J. 2022;24(4):80.","journal-title":"AAPS J"},{"key":"1666_CR8","unstructured":"EMA. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms_en.pdf. Accessed on 09 May 2025."},{"key":"1666_CR9","unstructured":"EMA. Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-equivalence-studies-demonstration-therapeutic-equivalence-locally-applied-locally-acting-products-gastrointestinal-tract-revision-1_en.pdf. Accessed on 09 May 2025."},{"key":"1666_CR10","unstructured":"Health Canada. Guidance document comparative pharmacokinetic studies for orally inhaled products. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/comparative-pharmacokinetic-studies-orally-inhaled-products-2020\/guidance-document-comparative-pharmacokinetic-studies-orally-inhaled-products-en.pdf. Accessed on 09 May 2025."},{"key":"1666_CR11","unstructured":"Health Canada. Guidance document conduct and analysis of comparative bioavailability studies. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/conduct-analysis-comparative.pdf. Accessed on 09 May 2025."},{"issue":"4","key":"1666_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/s11095-011-0662-8","volume":"29","author":"RA Lionberger","year":"2012","unstructured":"Lionberger RA, Raw AS, Kim SH, Zhang X, Yu LX. Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations. Pharm Res. 2012;29(4):1110\u201320.","journal-title":"Pharm Res"},{"issue":"2","key":"1666_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/pharmaceutics15020409","volume":"15","author":"V Mangas-Sanju\u00e1n","year":"2023","unstructured":"Mangas-Sanju\u00e1n V, Sim\u00f3n M, Gonz\u00e1lez-Rojano E, Ochoa D, Abad-Santos F, Rom\u00e1n M, et al. Alternative pharmacokinetic metrics in single-dose studies to ensure bioequivalence of prolonged-release products at steady state\u2014a case study. Pharmaceutics. 2023;15(2):409.","journal-title":"Pharmaceutics"},{"key":"1666_CR14","unstructured":"FDA. Partial AUCs 2.0\u2014improved metrics for assessing bioequivalence on mixed release mode (IR\/ ER) drug products; 2017. https:\/\/www.fda.gov\/media\/108390\/download. Accessed on 07 Mar 2026."},{"issue":"4","key":"1666_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1208\/s12248-012-9396-8","volume":"14","author":"L Endrenyi","year":"2012","unstructured":"Endrenyi L, Tothfalusi L. Metrics for the evaluation of bioequivalence of modified-release formulations. AAPS J. 2012;14(4):813\u20139.","journal-title":"AAPS J"},{"key":"1666_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejps.2014.10.001","volume":"66","author":"M Boily","year":"2015","unstructured":"Boily M, Dussault C, Massicotte J, Guibord P, Lefebvre M. The impact of new partial AUC parameters for evaluating the bioequivalence of prolonged-release formulations. Eur J Pharm Sci. 2015;66:70\u20137.","journal-title":"Eur J Pharm Sci"},{"key":"1666_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101135","volume":"41","author":"L Zhao","year":"2021","unstructured":"Zhao L, Li Z, Fang L, Kim MJ, Nallani SC, Sahajwalla CG, et al. Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidance. EClinicalMedicine. 2021;41:101135.","journal-title":"EClinicalMedicine."},{"issue":"4","key":"1666_CR18","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/cts.13004","volume":"14","author":"AG Sathe","year":"2021","unstructured":"Sathe AG, Brundage RC, Ivaturi V, Cloyd JC, Chamberlain JM, Elm JJ, et al. A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. Clin Transl Sci. 2021;14(4):1444\u201351.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1666_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11095-012-0862-x","volume":"30","author":"J Fourie Zirkelbach","year":"2013","unstructured":"Fourie Zirkelbach J, Jackson AJ, Wang Y, Schuirmann DJ. Use of partial AUC (PAUC) to evaluate bioequivalence\u2014a case study with complex absorption: methylphenidate. Pharm Res. 2013;30(1):191\u2013202.","journal-title":"Pharm Res"},{"issue":"5","key":"1666_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11095-018-2387-4","volume":"35","author":"LF Hsu","year":"2018","unstructured":"Hsu LF. Investigation of the discriminatory ability of pharmacokinetic metrics for the Bioequivalence Assessment of PEGylated Liposomal Doxorubicin. Pharm Res. 2018;35(5):106.","journal-title":"Pharm Res"},{"issue":"6","key":"1666_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5414\/CP204380","volume":"61","author":"M Liyanage","year":"2023","unstructured":"Liyanage M, Blaquera CL, Piscitelli J, Penzak SR, Nolin TD, Paine MF, et al. Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults. Int J Clin Pharmacol Ther. 2023;61(6):262\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"1666_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2165\/00003088-199529030-00002","volume":"29","author":"P Salv\u00e0","year":"1995","unstructured":"Salv\u00e0 P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet. 1995;29(3):142\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1666_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1208\/s12248-025-01158-y","volume":"28","author":"LF Hsu","year":"2025","unstructured":"Hsu LF. The role of early exposure metrics (pAUC0\u20133h and Cmax,0\u20133h) in assessing the bioequivalence of methylphenidate extended-release products\u2014a sensitivity analysis. AAPS J. 2025;28(1):11.","journal-title":"AAPS J"},{"issue":"9","key":"1666_CR24","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/add.13849","volume":"112","author":"G Mundin","year":"2017","unstructured":"Mundin G, McDonald R, Smith K, Harris S, Strang J. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. Addiction. 2017;112(9):1647\u201352.","journal-title":"Addiction"},{"issue":"5","key":"1666_CR25","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/cts.13053","volume":"14","author":"S Raofi","year":"2021","unstructured":"Raofi S, Kinjo M, Sun D, Li Z, Boyce H, Natarajan K, et al. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users. Clin Transl Sci. 2021;14(5):1977\u201387.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1666_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","volume":"58","author":"M Kinnunen","year":"2019","unstructured":"Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacokinet. 2019;58(6):705\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1666_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cpdd.468","volume":"8","author":"KA Schoedel","year":"2019","unstructured":"Schoedel KA, Gillespie M, Levy-Cooperman N, Shram MJ, Rabinovich-Guilatt L. Pharmacokinetic and pharmacodynamic correlations from 2 studies evaluating abuse potential of hydrocodone extended-release tablets. Clin Pharmacol Drug Dev. 2019;8(1):32\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1666_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106718","volume":"195","author":"HJ Wang","year":"2024","unstructured":"Wang HJ, Hsu LF. The role of partial area under the curve and maximum concentrations in assessing the bioequivalence of long-acting injectable formulation of exenatide\u2014a sensitivity analysis. Eur J Pharm Sci. 2024;195:106718.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1666_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/pharmaceutics17010021","volume":"17","author":"G Tsakiridou","year":"2024","unstructured":"Tsakiridou G, Angelerou MF, Efentakis P, Margaritis A, Papanastasiou AM, Kalantzi L. Partial AUCs in long-acting injectables: rationale, challenges, variability, usefulness, and clinical relevance. Pharmaceutics. 2024;17(1):21.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1666_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/FTD.0000000000000116","volume":"37","author":"JC Masters","year":"2015","unstructured":"Masters JC, Harano DM, Greenberg HE, Tsunoda SM, Jang IJ, Ma JD. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping. Ther Drug Monit. 2015;37(1):84\u20139.","journal-title":"Ther Drug Monit"},{"key":"1666_CR31","unstructured":"FDA. Draft guidance on octreotide acetate. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Octreotide%20acetate_inj_21008_RV02-14.pdf. Accessed on 08 May 2025."},{"key":"1666_CR32","unstructured":"EMA. Octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg and 30 mg product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/octreotide-acetate-depot-powder-and-solvent-suspension-injection-10-mg-20-mg-and-30-mg-product-specific-bioequivalence-guidance_en.pdf. Accessed on 08 May 2025."},{"key":"1666_CR33","unstructured":"FDA. Draft guidance on methylphenidate hydrochloride. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_212038.pdf. Accessed on 08 May 2025."},{"key":"1666_CR34","unstructured":"EMA. Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/methylphenidate-prolonged-release-tablet-18-mg-27-mg-36-mg-54-mg-modified-release-capsule-5-mg-10-mg-20-mg-30-mg-40-mg-50-mg-60-mg-product-specific-bioequivalence-guidance_en.pdf. Accessed on 08 May 2025."},{"key":"1666_CR35","unstructured":"EMA. Liposomal amphotericin B powder for dispersion for infusion 50 mg product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/liposomal-amphotericin-b-powder-dispersion-infusion-50-mg-product-specific-bioequivalence-guidance_en.pdf. Accessed on 08 May 2025."},{"key":"1666_CR36","unstructured":"EMA. Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/lanreotide-acetate-prolonged-release-solution-injection-prefilled-syringe-60-90-and-120-mg-productspecific-bioequivalence-guidance_en.pdf. Accessed on 08 May 2025."},{"key":"1666_CR37","unstructured":"FDA. Draft guidance on exenatide synthetic. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_022200.pdf. Accessed on 08 May 2025."},{"key":"1666_CR38","unstructured":"FDA. Draft guidance on budesonide. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Budesonide_ERTab_203634_RC12-14.pdf. Accessed on 08 May 2025."},{"key":"1666_CR39","unstructured":"EMA. Budesonide, prolonged release tablets, 9 mg product specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/budesonide-prolonged-release-tablets-9-mg-product-specific-bioequivalence-guidance_en.pdf-0. Accessed on 08 May 2025."},{"key":"1666_CR40","unstructured":"FDA. Draft guidance on budesonide https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_211929.pdf. Accessed on 08 May 2025."},{"key":"1666_CR41","unstructured":"EMA. Budesonide, gastro-resistant hard capsules, 3 mg, gastroresistant granules, 9 mg product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/budesonide-gastro-resistant-hard-capsules-3-mg-gastro-resistant-granules-9-mg-product-specific-bioequivalence-guidance_en.pdf-0. Accessed on 08 May 2025."},{"key":"1666_CR42","unstructured":"EMA. Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg\/ml product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/pegylated-liposomal-doxorubicin-hydrochloride-concentrate-solution-2-mgml-product-specific-bioequivalence-guidance_en.pdf. Accessed on 08 May 2025."},{"key":"1666_CR43","unstructured":"FDA. Guidance on Zolpidem. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Zolpidem_ERtab_21774_RC8-09.pdf. Accessed on 08 May 2025."},{"key":"1666_CR44","unstructured":"EMA. Ibuprofen oral use immediate release formulations 200\u2013800 mg product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/paracetamol-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance-revision-2_en.pdf. Accessed on 14 May 2026."},{"key":"1666_CR45","doi-asserted-by":"publisher","DOI":"10.18433\/j3vc8j","author":"EMA","year":"2026","unstructured":"EMA. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci. 2026. https:\/\/doi.org\/10.18433\/j3vc8j.","journal-title":"J Pharm Pharm Sci"},{"key":"1666_CR46","unstructured":"EMA. Tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/tadalafil-film-coated-tablets-25-mg-5-mg-10-mg-20-mg-product-specific-bioequivalence-guidance-revision-3_en.pdf. Accessed on 14 May 2026."},{"issue":"6","key":"1666_CR47","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s13318-016-0348-z","volume":"41","author":"LH Lee","year":"2016","unstructured":"Lee LH, Choi C, Gershkovich P, Barr AM, Honer WG, Procyshyn RM. Proposing the use of partial AUC as an adjunctive measure in establishing bioequivalence between deltoid and gluteal administration of long-acting injectable antipsychotics. Eur J Drug Metab Pharmacokinet. 2016;41(6):659\u201364.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1666_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106127","volume":"171","author":"KCC Soares","year":"2022","unstructured":"Soares KCC, Chiann C, Storpirtis S. Assessment of the impact of partial area under the curve in a bioavailability\/bioequivalence study on generic prolonged-release formulations. Eur J Pharm Sci. 2022;171:106127.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"1666_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/(SICI)1099-081X(199703)18:2<103::AID-BDD4>3.0.CO;2-S","volume":"18","author":"SK Niazi","year":"1997","unstructured":"Niazi SK, Alam SM, Ahmad SI. Partial-area method in bioequivalence assessment: naproxen. Biopharm Drug Dispos. 1997;18(2):103\u201316.","journal-title":"Biopharm Drug Dispos"},{"key":"1666_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106296","volume":"179","author":"P Gajjar","year":"2022","unstructured":"Gajjar P, Dickinson J, Dickinson H, Ruston L, Mistry HB, Patterson C, et al. Determining bioequivalence possibilities of long-acting injectables through population PK modelling. Eur J Pharm Sci. 2022;179:106296.","journal-title":"Eur J Pharm Sci"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01666-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:56Z","timestamp":1783748216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01666-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01666-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maheshwari Periyasamy and Mirunalini Ravichandran declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing not applicable to this article as no datasets were generated for it.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed to writing and revising the manuscript and have given approval to submit it.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}